APHINITY six-year results strengthen evidence of clinical benefit with Roche ’s Perjeta-based regimen

             Basel, 11 December 2019 - Roche (SIX: RO, ROG; OTCQX: RHHBY), the Breast International Group (BIG), Institut Jules Bordet Clinical Trials Support Unit (IJB-CTSU) and Frontier Science Foundation (FS) today announced data from a second interim overall survival (OS) analysis of the phase III APHINITY study, evaluating the combination of Perjeta® (pertuzumab), Herceptin® (trastuzumab) and chemotherapy (the Perjeta-based regimen) as an adjuvant (after surgery) treatment for patients with HER2-positive early breast cancer (eBC). This latest interim OS analysis was conducted after a median follow-up of approximately 74 months, compared to approximately 45 months for the primary analysis in 2017, and includes updated descriptive iDFS and cardiac safety data.1“The goal of adjuvant treatment is to give each person with early breast cancer the best chance of a cure,” said Levi Garraway, M.D., Ph.D., Chief Medical Officer and Head of Global Product Development. “These new data with longer follow-up show the continued effect of the Perjeta-based regime n and an increased invasive disease-free survival benefit.” Martine Piccart, M.D., Ph.D., BIG co-founder and Scientific Director at Institut Jules Bordet, added: “These results demonstrate the importance of longer follow-up of APHINITY and further confirm the Perjeta-based regimen as the standard of care for people with HER2-positive early breast cancer at high risk of recurrence, such as those with lym...
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news